New combo therapy shows promise for tough bone cancer

NCT ID NCT04803877

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times

Summary

This study tests a combination of two drugs, regorafenib and nivolumab, in people with osteosarcoma (a type of bone cancer) that has come back or not responded to treatment. The goal is to see if this combination can stop the cancer from growing longer than regorafenib alone. About 48 participants aged 5 and older will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Los Angeles

    Los Angeles, California, 90027, United States

  • Cincinnati Children's

    Cincinnati, Ohio, 45229, United States

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • Oregon Health and Sciences University

    Portland, Oregon, 97239, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.